The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Insulin degludec/liraglutide (Primary) ; Metformin; Sulfonylureas
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms DUAL IV
- Sponsors Novo Nordisk
- 23 Jan 2019 According to a Novo Nordisk media release, Xultophy was approved by Health Canada in April 2018 based on data from the DUAL clinical development program.
- 05 Oct 2018 Results of a post-hoc analysis from DUAL I-V and VII studies, presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 26 Jun 2018 Results of post-hoc analysis from (DUAL I-V and VII), were presented at the 78th Annual Scientific Sessions of the American Diabetes Association.